Abstract

Objective To investigate the treatment effect of a vascular-disrupting agent, M410, using diffusion-weighted imaging in a rabbit model of hepatic VX2 tumor. Methods 28 New Zealand white rabbit models with VX2 liver tumors were established and were randomly divided into M410 (intravenous injection of M410 at a dose of 25 mg/kg every three days) and control (intravenous injection of saline every three days) groups. Conventional and diffusion-weighted imaging (DWI) were acquired on a 3.0 T MR unit at baseline, 4 h, d 1, d 4, d 7, and d 14 posttreatment. B-value with 700 (s/mm2) was chosen during DWI examinations. Tumor volume and apparent diffusion coefficient (ADC) values of the entire tumor and solid component of the tumor at every time point were measured. Two randomly chosen rabbits from each group were sacrificed for H&E staining and CD34 immunohistochemical assessments at each time point. An independent sample t-test was used to assess differences in tumor sizes and ADC values of the entire tumor and solid component of tumors between two groups, with P < 0.05 considered statistically significant. Result There was no significant difference in tumor volume between the two groups at baseline, 4 h, and d 1. With time, the tumors in the control group grew significantly faster than those in the M410 group, and the average ADC values of the M410 group were lower than those of the control group at d 1 and higher than those of the control group at d 4; as such, there were statistical differences between the two groups at these two time points but not at the other four time points. The following pathological results reflected the underlying morphological changes and vascular alterations. Conclusions M410 performed well in inhibiting the growth of the hepatic VX2 tumor which could be noninvasively monitored by DWI metrics.

Highlights

  • Hepatocellular carcinoma is the second leading malignant tumor in the world

  • Since the diffusion of oxygen and nutrients in tissues remains limited, tumor angiogenesis is essential for the growth of tumors over 1–2 mm in diameter. e vascular system plays a key role in the survival and continuous growth of solid tumors, which are Canadian Journal of Gastroenterology and Hepatology known to be significantly attributed to treatment failures. e tumor vasculature is structurally immature, with clutter and leaky phenotypes, and the inherent differences between tumor vessels and normal tissue vessels make tumor vasculature a unique target for the noninvasive treatment of malignant tumors

  • We used diffusion-weighted imaging (DWI) for the first time monitoring the changes of rabbit VX2 liver tumor after treatment with a novel combretastatin A4 analogue, M410, at a cellular level and made a comparative analysis with the histopathological results

Read more

Summary

Introduction

Hepatocellular carcinoma is the second leading malignant tumor in the world. For years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been approved as a treatment option for patients with advanced HCC. Vascular disrupting agents (VDAs), unlike antiangiogenic therapies that inhibit the growth of new blood vessels, selectively target existing tumor vascular systems and disrupts the tumor vasculature [1,2,3]. Combretastatin A-4-phosphate (CA4P) is one of the most promising VDAs and has been widely used in targeted therapy and for the monitoring of tumors in various experimental studies [4,5,6,7]. It can disrupt the already formed vessel networks of growing tumors by inhibiting tubulin polymerization, resulting in extensive ischemic tumor necrosis. It can disrupt the already formed vessel networks of growing tumors by inhibiting tubulin polymerization, resulting in extensive ischemic tumor necrosis. is selective effect can be attributed to the presence of actin as another type of cytoskeleton in normal endothelial cells but is lacking in tumor endothelial cells. erefore, the normal vascular system is rarely affected by CA4P. e structural modification of molecules is known to be an effective way to obtain drugs with a better efficacy and lower toxicity, providing an important way to develop new drugs

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call